Encorafenib and Binimetinib Plus Pembrolizumab Versus Pembrolizumab for BRAF V600E/K Positive Melanoma
Status:
Recruiting
Trial end date:
2030-05-08
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, Phase 3 study to compare the
efficacy, safety, and tolerability of encorafenib and binimetinib plus pembrolizumab (Triplet
Arm) versus placebo plus pembrolizumab (Control Arm) in participants with metastatic or
unresectable locally advanced BRAF V600E/K mutation-positive melanoma.